Anti Amyloid Kisunla denied for missing prior authorization by Humana?

Humana's specific coverage criteria for anti amyloid kisunla are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Requires Prior Authorization for Kisunla — and How to Win It

Prior authorization (PA) for Kisunla (donanemab) is standard across most commercial and Medicare Advantage plans, including Humana. The denial is procedural rather than a judgment about your medical need — but a failed or incomplete PA can delay treatment by weeks or months. Understanding what Humana requires and documenting your case precisely against those criteria is the fastest path to approval.

## Why Prior Authorization Is Required

Kisunla is a high-cost specialty biologic with an amyloid-targeting mechanism. Humana's PA requirement exists to verify that the diagnosis of early symptomatic Alzheimer's disease has been confirmed, that amyloid pathology has been established through accepted testing, and that the patient's clinical profile aligns with the FDA-approved indication. Missing or imprecise documentation at the initial PA stage is the most common reason for denial.

## Federal Appeal Rights

If your prior-authorization request is denied:

• Internal appeal (ACA §2719 / ERISA §503): File a written appeal within the timeframe on the denial notice. The plan must reconsider under a full-and-fair review standard, meaning a reviewer who was not involved in the original denial must evaluate your appeal.
• Expedited appeal: If your physician certifies that waiting poses a serious risk to your health or ability to regain function, you may request expedited review — Humana must respond within 72 hours.
• External review: After exhausting internal appeals, request independent external review. The IRO is bound by medical evidence, not plan policy preferences, and its decision is final and binding on Humana.

## Documentation to Gather

1. Confirmed Alzheimer's diagnosis — Clinical notes documenting early symptomatic disease, including cognitive testing results and dates. 2. Amyloid confirmation — PET imaging report or cerebrospinal fluid analysis result demonstrating amyloid pathology consistent with the FDA-approved indication. 3. Neurological evaluation — Notes from the prescribing neurologist or specialist documenting clinical staging, functional status, and absence of factors that would preclude treatment per the FDA label. 4. Prescriber medical-necessity letter — A detailed letter from the neurologist stating that the patient meets the criteria in the FDA prescribing information, referencing the specific diagnostic evidence. 5. Humana's PA criteria — Obtain Humana's current published coverage policy for Kisunla and map each criterion to a specific chart fact.

## Criteria-Mapping Structure for Your PA Appeal

Review Humana's coverage policy alongside the FDA-approved prescribing label. For each criterion listed, document the exact matching evidence from the chart:

| Humana PA Criterion | FDA Label Alignment | Chart Evidence | |---|---|---| | Confirmed early symptomatic AD diagnosis | Approved indication | Specialist note + cognitive test date | | Amyloid pathology confirmed | Label requirement | PET or CSF report date and result | | Prescriber specialty | Per policy | Neurologist NPI and credentials | | Clinical staging consistent with label | Approved population | Cognitive assessment scale result |

Attach all source documents and ask Humana to identify, line by line, any criterion your submission did not satisfy.